Filing Analysis
📢 Regulation FD Disclosure
Filed May 15, 2026
⚪ LOW
PAVmed Inc. announced its financial results for the first fiscal quarter ended March 31, 2026, and provided a business update via a press release.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure)
- A press release was issued on May 15, 2026, and attached as Exhibit 99.1
- The report was signed by Dennis McGrath, President and CFO
📢 Regulation FD Disclosure
Filed Mar 30, 2026
⚪ LOW
PAVmed Inc. announced its financial results for the fiscal year ended December 31, 2025, and provided a business update via a press release on March 30, 2026.
📋 Key Facts
- The filing reports financial results for the fiscal year ended December 31, 2025.
- The report was filed on March 30, 2026, under Items 2.02 and 7.01.
- A press release detailing the results and business update is included as Exhibit 99.1.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
💸 Securities Offering
Filed Mar 27, 2026
🟡 MEDIUM
PAVmed Inc. stockholders approved several key proposals at a special meeting, including the issuance of common stock for the conversion of Series D Preferred Stock and debt refinancing. The meeting also resulted in a significant 1.5 million share increase to the company's 2014 Long-Term Incentive Equity Plan and a charter amendment regarding director removal.
🚩 Red Flags
- Significant potential dilution from the 700% increase in shares available under the 2014 Long-Term Incentive Equity Plan.
- Reliance on equity issuance (Series D Preferred and Convertible Notes) to refinance existing debt and redeem preferred stock.
- Charter amendment allowing director removal 'without cause' may indicate governance volatility or preparation for structural changes.
📋 Key Facts
- Stockholders approved the issuance of common stock upon conversion of 60,000 shares of Series D Preferred Stock sold in a February 3, 2026, private placement.
- Approval was granted for stock issuance related to an Amended and Restated Senior Secured Convertible Note used for debt refinancing.
- The 2014 Long-Term Incentive Equity Plan was amended to increase available shares by 1,500,000, raising the total from 213,517 to 1,713,517 shares.
- The Certificate of Incorporation was amended to allow the removal of any director with or without cause by a majority vote of outstanding voting power.
- The special meeting was held on March 27, 2026, with 54.1% of voting power represented.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.